PRNCR1在前列腺癌诊断及预后的价值

The value of PRNCR1 in the diagnosis and prognosis of prostate cancer

目的探讨前列腺癌非编码RNA1(PRNCR1)在前列腺癌早期诊断及预后的价值。方法选取2012年1月至2015年10月在本院诊治前列腺癌患者45例、良性前列腺增生患者88例,进行PRNCR1检验。结果PRNCR1检验的灵敏度84.4%(38/45)、特异度90.9%(80/88)、阳性预测值82.6%(38/46)、阴性预测值92.0%(80/87)、符合率88.7%(118/133),PRNCR1在前列腺癌组织中含量高于癌旁组织和良性前列腺增生组织,差异有统计学意义(P<0.05)。两年内转移、复发、肿瘤死亡患者30例,其PRNCRA表达量高于两年内无转移、复发、死亡的患者(15例),差异有统计学意义(P<0.05)。结论PRNCR1表达在诊断前列腺癌有价值,PRNCR1高表达与患者预后不良有关。

Objective To analyze the value of PRNCR1 in the early diagnosis and prognosis of prostate cancer. Methods From January 2012 to October 2015, the prostate cancer (n=45) and benign prostatic hyperplasia (n=88) tissues of surgical group were enrolled into PRNCR1 group and RNA test. Results The sensitivity of the 84.4%(38/45) PRNCR1 RNA test, specificity 90.9%(80/88), positive predictive value 82.6%(38/46), and negative predictive value of 92% (80/87), the coincidence rate was 88.7%(118/133), PRNCR1 in prostate cancer was higher than that of adjacent tissues and benign prostatic hyperplasia tissues, the difference was statistically significant (P<0.05). Within 2 years, tumor recurrence and metastasis object of 30 death cases of PRNCR1 cells was higher than that of 2 years without recurrence, metastasis, the object of 15 death cases, the difference was statistically significant(P<0.05). Conclusions The expression of PRNCR1 is valuable in the diagnosis of prostate cancer, and the high expression of PRNCR1 is associated with poor prognosis.